Pediatric Blood & Cancer最新文献

{"title":"Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.","authors":"Amanda E Marinoff, Allyson Thrall, Kathryn Aaronson, Benjamin S Braun, Maria Castellanos, Julia Chu, Michelle Hermiston, Benjamin J Huang, Anya Levinson, Erica Southworth, Beth Apsel Winger, Adam Olshen, Elliot Stieglitz","doi":"10.1002/pbc.31528","DOIUrl":"10.1002/pbc.31528","url":null,"abstract":"<p><strong>Background: </strong>Thrombopoietin receptor agonists (TPO-RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy-induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited.</p><p><strong>Methods: </strong>We retrospectively identified 15 pediatric and AYA patients aged 25 years or younger with hematologic malignancies treated with a TPO-RA at UCSF Benioff Children's Hospitals between 2015 and 2023. Platelet counts and transfusion requirements were compared before and after TPO-RA therapy.</p><p><strong>Results: </strong>The median age at TPO-RA initiation was 16 years (range: 7-25 years). Nine patients (60%) had a history of bleeding or comorbidity that predisposed to severe bleeding risk. Eleven patients received romiplostim and four patients received eltrombopag. The median platelet count significantly increased from 24 × 10⁹/L at baseline to 54 × 10⁹/L after 3 weeks of any TPO-RA therapy (p = 0.029). Monthly platelet transfusion requirements significantly decreased from a median of 15 to two units after TPO-RA therapy (p = 0.007). Fourteen of the 15 patients (93%) achieved a sustained platelet count >50,000/µL within 8 weeks, with a median time to response of 3 weeks. No TPO-RA-related adverse events were observed.</p><p><strong>Conclusion: </strong>TPO-RAs were effective in managing refractory thrombocytopenia in pediatric and young adult patients being treated for hematologic malignancies, with a favorable safety profile, even among patients with multiple comorbidities. These findings warrant further investigation through prospective clinical trials to confirm efficacy and establish clinical guidelines for this population.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31528"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access Program for Unapproved and Off-Label Drug Use in Pediatric BRAF V600E-Mutated Brain Tumors in Japan.","authors":"Maya Suzuki, Yuhki Koga, Terumi Kawasaki, Tamaki Ueda, Shunsuke Yamamoto, Hironori Goto, Junji Kishimoto, Eiko Ishida, Koji Todaka, Koh-Hei Sonoda, Yoshinao Oda, Yoshimoto Koji, Yasunari Sakai, Shouichi Ohga","doi":"10.1002/pbc.31510","DOIUrl":"10.1002/pbc.31510","url":null,"abstract":"<p><p>Programs allowing access to investigational drugs and off-label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese \"Patient-Proposed Healthcare Services\" evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off-label medications to four enrolled patients, two with low-grade glioma and two with high-grade glioma (median age: 10.5 years), until regulatory approval. The timeframe and data collection from such access programs need to be optimized for pediatric patients in accordance with the healthcare system of each nation.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 3","pages":"e31510"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Equitable Access to Psychosocial Screening in Canada: Validation of the French-Canadian Psychosocial Assessment Tool.","authors":"Émilie Trudel, David Ogez, Serge Sultan, Lisa-Sarah Brunier, Pascal Bernier, Marie-Claude Charrette, Émélie Rondeau, Leandra Desjardins","doi":"10.1002/pbc.31501","DOIUrl":"https://doi.org/10.1002/pbc.31501","url":null,"abstract":"<p><strong>Objective: </strong>The Psychosocial Assessment Tool (PAT) is a brief caregiver report, family-centered, psychosocial risk screening tool widely used in pediatrics and available in many languages. Although French is an official language of Canada, a French-Canadian version of the PAT has not yet been validated, which impedes access to this tool for family psychosocial screening. This study aimed to translate, adapt as necessary, and validate the French-Canadian version of the PAT.</p><p><strong>Methods: </strong>The PAT 3.0 was translated into French using the forward-backwards method. Interviews with healthcare workers (n = 5) and a focus group of parents of children newly diagnosed with cancer (n = 4) led to minor modifications to improve cultural adaptation and comprehensibility. Subsequently, 66 French-speaking parents of children newly diagnosed with cancer participated in a quantitative validation study; completing the French-Canadian PAT and related caregiver measures.</p><p><strong>Results: </strong>The French-Canadian PAT has an overall internal consistency of KR-20 = 0.64, with subscales ranging from 0.57 to 0.86. The total PAT score significantly correlated with the Distress Thermometer (r = 0.54). Congruent validity was demonstrated for most PAT subscales, except for Family Beliefs and Family Problems. The sample followed this distribution on the Pediatric Psychosocial Preventative Health Model: 21.2% universal, 53% targeted, and 25.8% clinical.</p><p><strong>Conclusion: </strong>The French-Canadian PAT provides insight into family psychosocial risk. This study is a step toward equitable access to care by providing French-speaking families with access to a tool aligned with the psychosocial standards of care in pediatric oncology. Future research should focus on implementing the PAT in Canadian clinical settings.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 3","pages":"e31501"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes Based on Histological Tumor Necrosis and Predictive Clinical and Laboratory Parameters for Necrosis in Children With Osteosarcoma Treated on a Non-High Dose Methotrexate-Based Chemotherapy Backbone.","authors":"Badira Cheriyalinkal Parambil, Poonam Khemani, Ajay Puri, Ashish Gulia, Maya Prasad, Venkata Ram Mohan Gollamudi, Mukta Ramadwar, Bharat Rekhi, Poonam Panjwani, Prakash Nayak, Manish Pruthi, Sajid Qureshi, Nilendu Purandare, Amit Janu, Akash Pawar, Komal Adhav, Girish Chinnaswamy","doi":"10.1002/pbc.31471","DOIUrl":"10.1002/pbc.31471","url":null,"abstract":"<p><strong>Background: </strong>Histopathological response to neoadjuvant chemotherapy (NACT) measured as tumor necrosis (TN) has been reported to be prognostic post-high-dose methotrexate (HDMTX)-based chemotherapy. We studied this on a non-HDMTX chemotherapy backbone.</p><p><strong>Materials and methods: </strong>Children ≤15 years, with osteosarcoma treated on OGS-2012 protocol and surgery post NACT from January 2013 to December 2020 were retrospectively analyzed. TN was expressed as percentage. Outcomes based on different TN cutoffs (used in a dichotomized manner dividing the cohort into two groups of less than/greater than the particular cutoff) and clinical-laboratory parameters predictive of TN were studied.</p><p><strong>Results: </strong>Analysis was done in 258 patients. Amputation was performed in 20.1%. Median TN was 94%. At a median follow-up of 38 months (range: 34-45 months), 3-year event free survival (EFS) and overall survival (OS) of the whole cohort were 56.1% (SE: 3.3%) and 87.8% (SE: 2.4%). For entire cohort, TN-70% (29.3% vs. 60.7%), 90% (38.7% vs. 69.0%), 100% (50.8% vs. 84.1%), were prognostic for EFS (p = 0.0001), while TN-90% (80.3% vs. 92.9%, p = 0.006) and 100% (85.5% vs. 97.7%, p = 0.023) were prognostic for OS. For localized disease, TN-70% (35.4% vs. 66.4%), 90% (41.6% vs. 77.0%), 100% (54.8% vs. 96.2%) were prognostic for EFS (p = 0.0001) and OS (p = 0.0001). For metastatic disease, TN-70% was prognostic for EFS (16.6% vs. 50.1%, p = 0.0047). Receiver-operator curve derived cutoff of 85.5% TN for EFS, 83.5% TN for OS prognosticated whole and localized cohorts the best. For metastatic cohort, 84.5% TN best prognosticated EFS. Among clinical-laboratory parameters, male gender (OR: 1.9, p = 0.01) and amputation (OR: 2.1, p = 0.014) had a higher risk of less than 90% TN.</p><p><strong>Conclusions: </strong>Tumor necrosis at 90% cutoff in localized disease is prognostic of survival even on a non-HDMTX-based backbone, but exploring other cutoffs for survival predictive and prognostic value could guide future treatment modification strategies and resource allocation in LMICs. Amputation, male gender predicts poor histological necrosis.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31471"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified G-CSF/ATG-Based Haploidentical Transplantation Protocol in Pediatric Primary Hemophagocytic Lymphohistiocytosis: A Long-Term Follow-Up Single-Center Experience.","authors":"Juan Xiao, Xingcheng Yang, Nanhai Wu, Shifen Fan, Zhouyang Liu, Fan Jiang, Jiao Chen, Jia Wei, Yuan Sun","doi":"10.1002/pbc.31495","DOIUrl":"10.1002/pbc.31495","url":null,"abstract":"<p><strong>Background: </strong>Primary hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome caused by immune dysregulation. Hematopoietic stem cell transplantation (HSCT) represents the only option for long-term cure for primary HLH. However, only around 25% of patients have a fully HLA-matched donor.</p><p><strong>Methods: </strong>In this retrospective study, we analyzed 42 pediatric patients with primary HLH who underwent haplo-SCT using the modified granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG)-based protocol. The conditioning regimen included 300-600 mg/m² etoposide (VP16), along with low doses of busulfan (Bu) (0.8-1.2 mg/kg every 6 hours on Days -8 to -6), cyclophosphamide (Cy) (10 mg/kg/day on Days -4 to -3), fludarabine (Flu) (30 mg/m²/day on Days -5 to -3), and ATG (8-9 mg/kg total dose on Days -5 to -2) to reduce complications.</p><p><strong>Results: </strong>All 42 patients achieved successful engraftment. Following a median follow-up period of 48.7 months, 32 of the 42 patients remained alive and disease free. The 2-year overall survival (OS) rate was 78.4%, and the 5-year OS rate was 73.7%. The 2-year failure-free survival (FFS) rate was 71.3%, and the 5-year FFS rate was 66.5%. Patients who achieved complete remission at the time of HSCT showed better OS (p < 0.05). The incidence of Grade III-IV acute graft-versus-host disease (GVHD) was 26.2%, and severe chronic GVHD was observed in 11.9% of patients. Thrombotic microangiopathy occurred in 13 patients, and veno-occlusive disease in two patients.</p><p><strong>Conclusions: </strong>This modified G-CSF/ATG-based haploidentical protocol demonstrates significant potential for pediatric patients with primary HLH, exhibiting commendable effectiveness and safety.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31495"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otoprotective Effects of Sodium Thiosulfate by Demographic and Clinical Characteristics: A Report From Children's Oncology Group Study ACCL0431.","authors":"Timothy J D Ohlsen, Willem H Collier, Jagadeesh Ramdas, Lillian Sung, David R Freyer","doi":"10.1002/pbc.31479","DOIUrl":"10.1002/pbc.31479","url":null,"abstract":"<p><strong>Background: </strong>ACCL0431 was a randomized clinical trial that demonstrated efficacy of sodium thiosulfate (STS) for preventing cisplatin-induced hearing loss (CIHL) among patients 1-18 years old. The purpose of this study was to evaluate possible differential STS otoprotection among patient subgroups.</p><p><strong>Procedure: </strong>This secondary analysis included ACCL0431 participants treated with cisplatin and randomized to receive STS or not (observation). Hearing status was obtained at 4 weeks and 12 months post cisplatin therapy (SIOP Ototoxicity Scale). Cumulative incidence of CIHL (Grade 1+) was assessed across age, sex, race/ethnicity, cancer diagnosis, and cisplatin infusion duration. Associations between these variables and CIHL were assessed using multivariable logistic regression. Interaction terms were used to evaluate potential heterogeneity in STS effect sizes across subgroups.</p><p><strong>Results: </strong>Among evaluable participants (n = 121), CIHL incidence was 22.4% with STS and 54.0% with observation. Odds of developing CIHL were greatest among children less than 5 years versus older (randomization-adjusted odds ratio [OR] 2.94, 95% CI: 1.30-7.14) and those with neuroblastoma, hepatoblastoma, or medulloblastoma versus germ cell tumor or osteosarcoma (age- and randomization-adjusted OR 11.26, 95% CI: 3.08-47.35). STS otoprotective effect sizes were also greatest in the same highest risk groups by age (<5 years: OR 0.08, 95% CI: 0.02-0.32; ≥5 years: OR 0.39, 95% CI: 0.15-1.06) and cancer diagnosis (neuroblastoma/hepatoblastoma/medulloblastoma: OR 0.1, 95% CI: 0.02-0.45; germ cell tumor/osteosarcoma: OR 0.32, 95% CI: 0.06-1.25). Significant otoprotection from STS was noted across other subgroups with varied magnitudes of effect.</p><p><strong>Conclusions: </strong>STS otoprotection appears to differ across clinically meaningful subgroups, particularly age at diagnosis. These results inform clinical decision-making and future research.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31479"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Pediatric, Adolescent, and Young Adult Patients With Fusion-Positive Alveolar Rhabdomyosarcoma Infiltrating Regional Lymph Nodes in the European CWS-2002P and RMS 2005 Studies and the Soft Tissue Sarcoma Registry.","authors":"Amadeus T Heinz, Melissa Ciuffolotti, Johannes H M Merks, Anton Schönstein, Véronique Minard-Colin, Jörg Fuchs, Gabriela Guillen, Beate Timmermann, Christian Vokuhl, Ewa Koscielniak, Julia C Chisholm, Monika Sparber-Sauer, Gianni Bisogno","doi":"10.1002/pbc.31476","DOIUrl":"10.1002/pbc.31476","url":null,"abstract":"<p><strong>Background: </strong>Patients with alveolar rhabdomyosarcoma (ARMS) with regional lymph node involvement (N1) are defined as \"very-high-risk rhabdomyosarcoma\" in Europe. Different chemotherapy regimens were used in European study protocols.</p><p><strong>Methods: </strong>Patients with FOXO1 fusion-positive N1 ARMS registered in the CWS-2002P study, the EpSSG RMS 2005 study, and SoTiSaR were retrospectively investigated. Patients received systemic treatment with chemotherapy (CHT) and local treatment of primary tumor (PT) and involved lymph nodes (LN) with radiotherapy (RT) and/or surgery. Kaplan-Meier estimators and Cox regression were used to examine event-free survival (EFS) and overall survival (OS) according to prognostic factors and treatment.</p><p><strong>Results: </strong>A total of 156 patients registered in RMS 2005 (n = 99), CWS-2002P (n = 20), and SoTiSaR (n = 37) between 2003 and 2020 were eligible for this analysis. Median age at diagnosis was 10.2 years [0.1-21.9]. Treatment comprised CHT with IVADo (ifosfamide, vincristine, actinomycin-D, doxorubicin, n = 93; 60%), VAIA (vincristine, actinomycin-D, ifosfamide, adriamycin/doxorubicin, n = 53; 34%) or other regimens (n = 10; 6%); resection of the PT (n = 89; 57%), LN sampling or dissection (n = 92; 59%), and/or RT (n = 139; 89%). Maintenance treatment (MT) was added in n = 99/135 (73%) patients who achieved complete remission. Five-year EFS and OS of the cohort were 45% and 47%, respectively. Age and tumor size were independent prognostic factors for EFS. Local treatment applied to the LN with surgery, RT or both significantly improved EFS (p = 0.02) and OS (p = 0.04), with no difference between the modalities (p = 0.7).</p><p><strong>Conclusions: </strong>Patients with fusion-positive N1 ARMS carry a poor prognosis. Adequate local treatment of LN improved survival.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31476"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Feasibility of an Exercise Intervention Including Physical Assessment During the First 6 Months of Cancer Treatment in Children and Adolescents in a Randomized Controlled Trial.","authors":"Peter Schmidt-Andersen, Anna Pouplier, Avery D Faigenbaum, Christina Kirkeby Beth, Clara Cæcilie Olsen, Sine Lykkedegn, Henrik Hasle, Klaus Müller, Hanne Baekgaard Larsen, Martin Fridh, Jan Christensen","doi":"10.1002/pbc.31498","DOIUrl":"10.1002/pbc.31498","url":null,"abstract":"<p><strong>Purpose: </strong>The aim was to assess the feasibility of a randomized controlled exercise intervention, including physical assessments, in children and adolescents during the first 6 months of cancer treatment.</p><p><strong>Materials and methods: </strong>A sample of children and adolescents (n = 84, 6‒17.9 years) from an ongoing trial (INTERACT: NCT04706676) was randomly assigned to an integrative neuromuscular training (INT) intervention or active control intervention during treatment. The following inter-related feasibility domains were assessed: availability, acceptance, and attrition. Further, we assessed adherence to INT and physical assessments. Adverse events related to exercise and physical assessments were also reported.</p><p><strong>Results: </strong>We found feasible rates within the availability and attrition domains. While the INT group demonstrated feasible group-level adherence rates, individual adherence to prescribed intervention demands was suboptimal. Physical assessments after 6 months of cancer treatment showed feasible rates.</p><p><strong>Conclusion: </strong>This study offers insights into the feasibility of an early-initiated INT intervention designed for children and adolescents undergoing cancer treatment. To ensure an optimal frequency of exercise in future studies, a flexible approach to hospital-based INT and a structured strategy for home-based exercise should be considered. Future trials should prioritize outcomes to minimize the length and timing of assessment.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31498"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of accidental live attenuated virus vaccination during treatment of a child with acute lymphoblastic leukemia.","authors":"Marc Bienias, Svenja Feldmann, Angela Wawer, Andreas Osterman, Stephan Böhm, Oliver T Keppler, Julia Hauer","doi":"10.1002/pbc.31398","DOIUrl":"10.1002/pbc.31398","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31398"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Bone Marrow Necrosis and Fat Embolism Syndrome Without Long-Term Sequelae in a Young Adult with Sickle Cell Disease: A Case Report and Recommendations for Diagnosis and Management.","authors":"Chelsea L Haynes, Ana Guimaraes, Shagun Vashisth, Evelisse Viamonte, Jennifer J G Welch, Bradley Denardo, Manpreet Kochhar, Lydia Musula, Diana O Treaba, Sarah Welsh, Patrick T McGann","doi":"10.1002/pbc.31537","DOIUrl":"10.1002/pbc.31537","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31537"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142952855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}